Compare KSS & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSS | MESO |
|---|---|---|
| Founded | 1962 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 1995 | 2005 |
| Metric | KSS | MESO |
|---|---|---|
| Price | $17.67 | $17.19 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 15 | 1 |
| Target Price | ★ $15.31 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 176.4K |
| Earning Date | 05-28-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | ★ 142.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $629.74 |
| Revenue Next Year | $0.21 | $30.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.38 | $12.66 |
| 52 Week High | $25.22 | $21.50 |
| Indicator | KSS | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 55.82 |
| Support Level | $17.06 | $16.67 |
| Resistance Level | $20.09 | $17.10 |
| Average True Range (ATR) | 0.84 | 0.36 |
| MACD | -0.24 | 0.06 |
| Stochastic Oscillator | 32.46 | 55.25 |
Kohl's is the second-largest traditional US department store company by sales. It has about 1,150 stores in 49 states and offers moderately priced private-label (31% of 2025 sales) and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most (about 80%) of its stores are in strip centers. Kohl's also has a large digital sales operation (29% of 2025 sales). Women's apparel is the retailer's largest category, having generated 24% of its 2025 sales. Kohl's is headquartered in Menomonee Falls, Wisconsin, and was founded in 1962.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.